In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How to Earn the Economic Payback Diagnostics Companies Deserve

Executive Summary

For most diagnostics companies, the prospect of premium pricing has been an elusive dream. The health care landscape is peppered with expensive novel drugs priced to underscore their clinical impact on patient care. A similar strategy for pricing novel diagnostics with significant clinical impact makes sense, especially since many of them are driving the decisions to deploy novel drugs in the first place. Now, strong system economics arguments are becoming more mainstream and payors are beginning to reward companies with reimbursement of their premium priced tests, based upon rigorous clinical arguments supporting the diagnostics' benefits to clinical decision-making and compelling economic arguments customized to each major payer.
Advertisement

Related Content

Is Diagnostics the New Biotech...and Will Pharma Embrace It?
Is Diagnostics the New Biotech...and Will Pharma Embrace It?
CardioDx: Bringing Molecular Diagnostics Into the Cardiovascular Arena
Leveraging Assay Platforms to Create Category-Killer Diagnostic Tests
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q1 2009
The Pace of Development of Molecular Imaging Agents
New Initiatives to Improve Diagnostic Data Access
What New Her2 Tests Say about Personalized Medicine
Biomarker Diagnostics: Place Your Bets Wisely
Medco: Market Multiplier for Personalized Medicine

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel